Log in to save to my catalogue

Comparison between tofacitinib and ustekinumab as a third‐line therapy in refractory ulcerative coli...

Comparison between tofacitinib and ustekinumab as a third‐line therapy in refractory ulcerative coli...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11176899

Comparison between tofacitinib and ustekinumab as a third‐line therapy in refractory ulcerative colitis: A multicenter international study

Publication information

Publisher

England: John Wiley & Sons, Inc

More information

Scope and Contents

Contents

Background
Ustekinumab and tofacitinib have recently been approved for the management of moderate to severe ulcerative colitis (UC). However, there is no evidence on how they should be positioned in the therapeutic algorithm. The aim of this study was to compare tofacitinib and ustekinumab as third‐line therapies in UC patients in whom anti‐TNF...

Alternative Titles

Full title

Comparison between tofacitinib and ustekinumab as a third‐line therapy in refractory ulcerative colitis: A multicenter international study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11176899

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11176899

Other Identifiers

ISSN

2050-6406,2050-6414

E-ISSN

2050-6414

DOI

10.1002/ueg2.12492

How to access this item